Vertex Pharmaceuticals/VRTX

$426.25

-1.08%
-
1D1W1MYTD1YMAX

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Ticker

VRTX

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Leiden

Employees

5,400

Headquarters

Boston, United States

VRTX Metrics

BasicAdvanced
$111.97B
Market cap
31.20
P/E ratio
$13.89
EPS
0.36
Beta
-
Dividend rate

What the Analysts think about VRTX

Analyst Ratings

Majority rating from 31 analysts.
Buy

Price Targets

Average projection from 24 analysts.
9.21% upside
High $578.00
Low $325.00
$426.25
Current price
$465.50
Average price target

VRTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
38.47% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$2.52B
1.38%
Net income
$968.8M
-6.42%
Profit margin
38.47%
-7.7%

VRTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.37%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$3.05
$3.89
$4.08
$4.20
-
Expected
$3.00
$3.88
$3.97
$4.10
$4.04
Surprise
1.78%
0.21%
2.67%
2.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Vertex Pharmaceuticals stock

Buy or sell Vertex Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing